Telix is pioneering a new cancer modality

We are passionate about improving the quality of life for people with cancer and rare diseases. And we put our patients at the heart of everything we do.

With over 20 clinical trials underway worldwide across a range of diseases, Telix is at the forefront of theranostic drug development.

Telix clinical trials

Telix is pushing the frontiers of diagnostic and therapeutic nuclear medicine through a number of clinical trials, both company-sponsored and in collaboration with leading cancer centres around the globe.

See below list of Telix trials that are currently active. A full listing of Telix clinical trials which also includes active and completed studies can be found at

Prostate cancer / PSMA

Name / StudyStudy TitleSponsorAssetDiseaseInterventionPhaseStatusLocation
China Registration Study

Study ID: NCT05847348
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese PatientsTelixTLX591-CDxProstate Cancer ImagingIIIRecruitingChina
NOBLE Registry

NOBLE Registry
The NOBLE Registry is collecting prospective, real-world clinical data on the use of Telix’s SPECT-based investigational imaging product TLX599-CDx (99m Tc-iPSMA)Telix and Oncidium FoundationTLX599-CDxProstate CancerImagingNARecruitingGlobal

Study ID: NCT04876651
177Lu-DOTA-rosopatamab With Best Standard of Care (SoC) for the Second Line of Treatment for Metastatic Castrate-resistant Prostate Cancer, which Expresses PSMATelixTLX591Prostate CancerTherapyIIIRecruitingGlobal

Study ID: NCT05146973
External Beam Therapy with Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer. A collaborative study with GenesisCareTelixTLX591Prostate CancerTherapyIIRecruitingAustralia

Study ID: NCT04726033
64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) (CUPID)TelixTLX592Prostate CancerTherapy (2nd Gen)IRecruitingAustralia

Kidney cancer / CAIX

Name / StudyStudy TitleSponsorAssetDiseaseInterventionPhaseStatusLocation
ZIRCON China StudyTLX250-CDx for PET/CT Imaging of ccRCC in Chinese PatientsTelixTLX250-CDxKidney CancerImagingIIIStart-upChina

Study ID: NCT06090331
TLX250-CDx US Expanded Access Program (EAP)TelixTLX250-CDxKidney CancerImagingEAPRecruitingUS
TLX250-CDx EU NPPTLX250-CDx EU Named Patient Pathway (NPP)TelixTLX250-CDxKidney CancerImagingNPPRecruitingNetherlands

Study ID: NCT05663710
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCMD Anderson Cancer CenterTLX250Kidney CancerTherapyIIRecruiting US

Study ID: NCT05239533
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney CancerMemorial Sloan Kettering Cancer CenterTLX250Kidney CancerTherapyIIRecruitingUS

Study ID: NCT05046665
A Single-centre, Open-label, Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET in Urothelial Cancer PatientsSouth Metropolitan Health ServiceTLX250-CDxBladder or Urothelial CancerImagingIRecruitingAustralia

Study ID: NCT05563272
Exploration of CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.TelixTLX250-CDxCAIX Expressing Solid TumorsImagingIIRecruitingUS

Study ID: NCT05868174
Evaluation of different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.TelixTLX250CAIX Expressing Solid Tumors TherapyIbRecruiting Australia

Glioblastoma / LAT-1

Name / StudyStudy TitleSponsorAssetDiseaseInterventionPhaseStatusLocation

Study ID: NCT05450744
131I-TLX-101 for Treatment of Newly Diagnosed GlioblastomaTelixTLX101GlioblastomaTherapyI/IIRecruitingAustralia, New Zealand
IPAX-LinzTBCKepler University HospitalTLX101GlioblastomaTherapyIIRecruitingAustria

Sarcoma / PDGFRα

Name / StudyStudy TitleSponsorAssetDiseaseInterventionPhaseStatusLocation
TLX300-CDx in STSPhase I Study of 89Zr-labelled olaratumab in Soft Tissue Sarcoma (STS)TelixTLX300-CDxSTSImagingIStart-upAustralia

Bone marrow conditioning / CD66

Name / StudyStudy TitleSponsorAssetDiseaseInterventionPhaseStatusLocation
TLX66 in AMLPhase II Study of 90Y-labelled Anti-CD66 antibody in Acute Myeloid Leukaemia (AML)TelixTLX66AMLTherapyIIIn planningAustralia

Study ID: NCT04856215
Open Label, Phase II Study of 90Y-labelled Anti-CD66 ab in Childhood High Risk LeukaemiaGreat Ormond Street HospitalTLX66Pediatric LeukemiaTherapyIIRecruitingUK

Compassionate use

Telix is often contacted to provide access to our products under compassionate use. We respect the treatment journey of the patient and the independence of healthcare professionals in making their treatment decisions. Telix tries to accommodate such requests whenever it is clinically, ethically and practically feasible to do so.

You can find Telix’s compassionate use policy here:

Request EAP/Compassionate Use Dose

    I am a...

    Compound/Product Requested